Dataset and R script to reproduce the analyses of the manuscript: Vinh-Hung V, Gorobets O, Adriaenssens N, Van Parijs H, Storme G, Verellen D, Nguyen NP, Magne N, De Ridder M. Lung-heart outcomes and mortality through the 2020 COVID-19 pandemic in a prospective cohort of breast cancer radiotherapy patients. Cancers 2022; 14(24):6241. https:// doi.org/10.3390/cancers14246241 https://www.mdpi.com/2072-6694/14/24/6241 PubMed: PMID: 36551726 PMCID: PMC9777311 Info on the variables in file "aelq6_public.R" reproduced in "aelq_2_3_readme.txt": "aelq2_base2.txt" = baseline characteristics. "aelq3.txt" = longitudinal maesurements. Variables in "aelq2_base2.txt": "aelq2_base2.txt" = baseline characteristics. # Age at randomization, years. # RTdose: cf TomoBreast papers. # 51 Gy = hypofractionated, simultaneous integrated boost# 42 Gy = hypofractionated, no boost, mastectomy cases only# 50 Gy = conventional, no boost, mastectomy cases only# 66 Gy = conventional, sequential boost# Weight kg, Height cm, # Detection 1=found by screening (senology follow-up/controle)# 2=found by symptoms (pain, palpable)# 9=unknown# Smoker 0= Not smoker# 1= Smoker# 2=ex-smoker# Mastectomy (and other binary coded) 1= yes# chemosched 0=none# 1= planned after RT (sequential)# 2= prior to RT and is finished (sequential)# 3= chemo is on-going or is planned to start with RT (concomitant)# hormonetherapy 0=no# 1=tamoxifen (nolvadex)# 2=Femara (Letrozole)# 3=zoladex# 4=tamoxifen + zoladex# Laterality 1,=Right, 2=Left, 3=Bilateral# LengthFU: length of follow-up, days from randomization "aelq3.txt" = longitudinal maesurements.# "Nr" = Case ID# "Time" in days from origin (origin =date of randomization), # if negative =before randomization# "KPS" "Weight" # "Died" "LocalRec" "Metast" "NewPrim" = binary code, 0=no, 1=yes# "fAEBreast" "fAEHeart" "fAELung" "fAEOther" # fAE = freedom from breast, heart, lung, other adverse event score# "LVEF2" = ejection fraction, %# "MacIver" = estimated cardiac strain # the following are pulmonary function tests, untransformed units# "FVC", "FEV1", "PEF", "VC", "TLC", "RV", "FRC", "Raw", "sRaw", "DLCO",# "VA", "PF" # "fDY", "fFA", "fPA" = freedom from dyspnea, from fatigue, from pain# range 0 to 100 (best)# see papers: # Van Parijs, H.; Vinh-Hung, V.; Fontaine, C.; Storme, G.; Verschraegen, C.;# Nguyen, D.M.; Adriaenssens, N.; Nguyen, N.P.; Gorobets, O.; De Ridder, M.# Cardiopulmonary-related patient-reported outcomes in a randomized clinical# trial of radiation therapy for breast cancer. BMC Cancer 2021, 21, 1177,# doi:10.1186/s12885-021-08916-z. # preprint:# Van Parijs, H.; Cecilia-Joseph, E.; Gorobets, O.; Storme, G.; # Adriaenssens, N.; Heyndrickx, B.; Verschraegen, C.; Nguyen, N.P.;# De Ridder, M.; Vinh-Hung, V. Lung-heart toxicity in a randomized # clinical trial of hypofractionated image guided radiation therapy for# breast cancer. Preprints 2022, 202212, 0214.# https://doi.org/10.20944/preprints202212.0214.v1 # # "Year" = year of the observation# example: randomized 1/1/2011, measurement done 1/31/2011, time = 30 days,# Year =2011# 

Lung-heart toxicity in a randomized clinical trial of hypofractionated image guided radiation therapy for breast cancer. Van Parijs H, Cecilia-Joseph E, Gorobets O, Storme G, Adriaenssens N, Heyndrickx B, Verschraegen C, Nguyen NP, De Ridder M, Vinh-Hung V.Front Oncol. 2023 Nov 20;13:1211544. doi: 10.3389/fonc.2023.1211544. eCollection 2023.PMID: 38053657 https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1211544/full